Key Details
Price
$2.52Annual ROE
-31.49%Beta
2.41Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Feb 5, 2025Recent annual earnings:
Aug 14, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Accuray Incorporated (NASDAQ:ARAY ) Q2 2025 Results Conference Call February 5, 2025 4:30 PM ET Company Participants Jesse Chew - Chief Legal Officer Suzanne Winter - President and Chief Executive Officer Ali Pervaiz - Chief Financial Officer Conference Call Participants Marie Thibault - BTIG Brooks O'Neil - Lake Street Capital Markets Operator Good day, and welcome to the Accuray Fiscal 2025 Second Quarter Financial Results Conference Call. All participants will be in a listen-only mode.
Although the revenue and EPS for Accuray (ARAY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Accuray (ARAY) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.10 per share a year ago.
MADISON, Wis. , Jan. 23, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Shandong Cancer Hospital and Institute has achieved a milestone with the completion of treatment for 100 patients using the Tomo® C Radiation Treatment Delivery System, a product built in China through the CNNC-Accuray joint venture.
MADISON, Wis. , Jan. 21, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Leonel Peralta is joining the company as Senior Vice President, Chief Operations Officer, effective February 3, 2025.
Accuray (ARAY) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Accuray announces the approval of the Chinese NMPA for its latest radiation therapy solutions.
MADISON, Wis. , Jan. 13, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company's Radixact SynC™ System and CyberKnife® S7™ System have been approved by the Chinese National Medical Products Administration (NMPA).
ARAY's solid product demand and revenue growth raise optimism about the stock.
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Accuray (ARAY) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
FAQ
- What is the ticker symbol for Accuray Incorporated?
- Does Accuray Incorporated pay dividends?
- What sector is Accuray Incorporated in?
- What industry is Accuray Incorporated in?
- What country is Accuray Incorporated based in?
- When did Accuray Incorporated go public?
- Is Accuray Incorporated in the S&P 500?
- Is Accuray Incorporated in the NASDAQ 100?
- Is Accuray Incorporated in the Dow Jones?
- When was Accuray Incorporated's last earnings report?
- When does Accuray Incorporated report earnings?
- Should I buy Accuray Incorporated stock now?